The relationship between a cutting-edge technology and the venture capital industry is said to make or break the technology. The key question to be answered is: has Australia made the VC-Biotech relationship work? More
The FDA outdid itself last year, granting first-time approvals to 43 new biotech-derived medicines and 36 supplemental indications for drugs and biologics developed by specialty and big pharma companies as well as biotech firms. More
Few women claim the title of CEO in Biotechnology companies, here a handful of female CEOs explain their journey to the top of the corporate world. More
At the Financial Times' Global Biotech Conference, industry experts gathered to discuss key issues facing the biotechnology industry. Two presentations and a panel discussion were devoted to one of the hottest topics - biogenerics. More
This article aims to explore the current state of UK patent law in relation to the issue of sufficiency, particularly in the light of the recent decision in the patent dispute between Amgen and Transkaryotic Therapies Inc. More
The first annual RNAi Europe conference and exhibition organised by Select Conferences attracted over 160 delegates including representatives from large pharmas, biotech companies academia and technology providers. More
Intellectual property rights are essential in today's technology-driven age. Building a strategic IP portfolio is economically important from both an offensive and defensive standpoint. More
Stem cells might be the most remarkable of the body's entire cellular repertoire. Unlike most other cells, stem cells are capable of self-renewal and can differentiate into one, several or all the tissues in the human body. More
All rights reserved. Terms and Conditions | Contact us
